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Does articaine, rather than lidocaine, increase the 
risk of nerve damage when administered for inferior 
alveolar nerve blocks in patients undergoing local 
anaesthesia for dental treatment? A mini systematic 
review of the literature
P. Stirrup*1 and S. Crean2
The reason for articaine’s popularity appears 
to be due to its efficacy. Numerous studies have 
shown that articaine produces a more profound 
anaesthesia than that of lidocaine.2–8 Lidocaine 
is an amide compound, based on a benzene ring 
structure (C6H6). Articaine, in contrast, possesses 
a thiophene ring (C4H4S), providing greater lipid 
solubility and an increased potency as a greater 
volume of an administered dose can enter the 
target neurons. Articaine’s lipid solubility has 
been quoted at over four times greater than that 
of lidocaine.9 The same study confirmed that the 
onset of anaesthesia was achieved in 7.4 mins with 
articaine, as opposed to 8.7 mins with lidocaine.9 
It has also been suggested that articaine provides 
a longer duration of anaesthesia due to its protein 
binding characteristics.10,11
With these attributes, it is perhaps not sur-
prising that many studies have concluded that 
Introduction
Since 1949, lidocaine has been recognised as 
the ‘gold-standard’ of local anaesthetic (LA) 
agents.1 However, the desire to develop fast-
acting agents with a short half-life that also 
produce profound anaesthesia has led to 
the development of other alternatives. One 
example is articaine, initially synthesised in 
1969 and used for the first time in clinical 
dental practice in Germany in 1976.
Aims  This mini systematic review seeks to analyse the available literature and determine if a 4% articaine solution poses a 
greater risk of inferior alveolar and/or lingual nerve damage compared to that of 2% lidocaine, when administered for an 
inferior alveolar nerve block. Results  After a mini systematic review of the published literature, seven suitable studies were 
identified: one double-blind random controlled trial (DBRCT) and six retrospective cohort studies. The DBRCT and two of 
the cohort studies concluded that 4% articaine poses no greater risk of nerve damage. The remaining four cohort studies 
suggested that caution should be exhibited when using a 4% local anaesthetic solution rather than a 2% solution. However, 
these studies also concluded that no evidence exists to explain the reasons for their results. Discussion and conclusion  The 
included articles present no conclusive evidence to suggest that 4% articaine causes more nerve damage than 2% lidocaine, 
although some authors advise caution when using this agent. All studies conclude that further quality research is required, 
and it is therefore suggested that dental practitioners exhibit caution when choosing to use 4% articaine in an inferior 
alveolar nerve block until further scientific research has been performed.
articaine is more efficient at producing profound 
anaesthesia than lidocaine.6,12–15 These papers 
include studies of both infiltration and nerve 
block anaesthesia. Other authors concluded that 
articaine has a faster onset than lidocaine,11 and a 
meta-analysis has proved that articaine is 1.6–3.5 
times more potent than lidocaine.2 Several studies 
have concluded that articaine should be recom-
mended for use over lidocaine.2,6,12,16 In 2007, 
Robertson et al. concluded that both the speed 
of onset and the anaesthetic efficacy of articaine 
were superior to those of lidocaine, when admin-
istered via a buccal infiltration technique in the 
posterior molar region.14
Another important attribute of a local anaes-
thetic agent is that of safety and this is perhaps 
where articaine compares less favourably. Since its 
introduction, several articles have been published 
warning of possible nerve damage when articaine 
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is administered in an inferior alveolar nerve 
block (IANB).17,18 These articles indicate a risk 
of causing temporary or permanent paraesthesia 
of the inferior alveolar nerve (IAN) but evidence 
also exists contradicting these claims.3,19,20
It appears, therefore, that the dental profes-
sion faces a dilemma. Should the more efficient 
agent be used to achieve faster, more profound 
anaesthesia; or should the profession be wary 
of an agent that may have the potential to 
induce nerve damage?
A mini systematic review of the literature 
was performed by a single researcher with 
one, clearly focused question.21 The results 
of the study will hopefully provide advice to 
the dental profession, ensuring the continued 
provision of safe and effective local anaesthesia.
Methodology
The Scottish Intercollegiate Guidelines 
Network (SIGN) presents eight levels of 
evidence-based research. The SIGN tool was 
used in this study according to the criteria 
set out in Table 1.22 The development of the 
research question was aided using the PICOS 
method,23 as described in Table 2. Inclusion 
and exclusion criteria were applied to the lit-
erature search as outlined in Tables 3 and 4. 
Basic search terms and medical sub-headings 
terms were developed and detailed in Boxes 1 
and 2. Three electronic databases were chosen 
to systematically search the available literature:
1. MEDLINE with Full Text
2. Dentistry & Oral Sciences Source
3. The Cochrane Library.
Quality assessment of studies
To ensure that the random controlled trials 
included in the review were accurately assessed 
against the inclusion and exclusion criteria, the 
risk of bias tool as described in the Cochrane 
Handbook for Systemic Reviews of Intervention 
was applied.24
For the selected cohort studies, a meth-
odology index for non-randomised studies 
(MINORS) was applied,25 as described in Table 
6. A record sheet was developed, and each 
study was subsequently scored as directed by 
Slim and Nini et al. 200325 as defined in Table 7.
Data extraction
Specifically designed data extraction forms 
were developed, allowing uniform data to be 
extracted under the following headings:
• Study design
• Study objectives
• Geographical origin of the study
• Clinical setting for the study
• Study funding
• Study participants – sex, age, numbers
• Type of anaesthetic agent used
• Study outcome–methods of recording and 
reporting nerve damage
• Comparison made between ‘expected’ and 
‘observed’ outcomes
• Follow-up periods
• Attrition bias
• Data analysis of outcomes.
Results
Data extraction and results of the mini systematic 
review are detailed in Tables 8–15 and Figure 1.
Discussion
Malamed and Gagnon’s study of 1,325 partici-
pants enabled a statistical analysis of the results 
which indicated that the incidence of nerve 
damage was the same (1%) whether 4% articaine 
or 2% lidocaine was used as the LA agent. Indeed, 
this DBRCT concluded that articaine is a ‘safe 
and effective’ local anaesthetic agent.19
Both studies conducted by Pogrel,20,26 
concluded that the incidence of nerve damage 
following the use of 4% articaine was in pro-
portion to its market share. However, three 
of the studies indicated that the use of 4% 
articaine elicited more adverse outcomes than 
would be expected when compared to the 
agent’s market share.17,27,28
Limitations and characteristics of 
included studies
Several methodological inconsistencies exist 
throughout the included studies, making a 
direct comparison between the chosen articles 
difficult. When performing a study comparing 
two pharmaceutical agents, a true comparison 
can only be achieved with the knowledge of the 
relative use of the two drugs within the studied 
population. Haas and Lennon,17 Gaffen and 
Haas,28 and Garisto, Gaffen et al.,27 all used the 
‘null hypothesis’ developed by Ronald Fisher.29 
However, the other included studies failed to 
indicate any comparison between expected 
and observed outcome events.
The creation of a ‘barb’ on the tip of the needle, 
resulting from contact with the bone, may also be 
a factor in the traumatic damage to both the IAN 
and lingual nerve (LN). However, whether or 
not this event occurred during any of the IANBs 
included in the studies, the resultant mechanical 
damage would be the same for both LA solutions.
Of the seven included papers, only one involves 
a DBRCT, three involve voluntary reporting of 
nerve damage, and the remaining three articles 
elicit their information from patients who have 
been referred to a specialist centre for the specific 
reason that they are experiencing some degree of 
nerve damage. This clearly results in a consider-
able degree of reporting bias.
With incidences of nerve damage ranging 
from 1:27,000 to 1:785,000,17,30 it is clear 
that this study’s outcome is extremely rare. 
To obtain statistically significant results in a 
DBRCT would require a clinical trial on a very 
large scale. This could explain the existence of 
only one such study since 1976.19
Both Hillerup and Jensen,18 and Garisto and 
Gaffen,27 make reference to the possibility of 
reporting bias in their papers, and Gaffen and 
Haas28 admit that ‘reported incidence numbers 
should be viewed cautiously.’ In his 2007 paper, 
Pogrel26 states that he estimates his study 
represents approximately 10% of all cases of 
nerve damage in the given population per year. 
However, reporting bias for patients referred to 
Box 1  Basic search terms
articaine
carticaine
septanest
ultracaine
septocaine
dental anaesthesia
lignocaine
lidocaine
xylocaine
paraesthesia
paresthesia
anaesthesia
anesthesia
dysaesthesia
dysesthesia
trigeminal nerve injuries
damage
injury
inferior alveolar nerve
inferior dental nerve
mandibular nerve
lingual nerve
Box 2  Medical sub headings terms 
(MeSH Terms)
articaine
dental anaesthesia
nerve injury
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a specialist centre would be the same for both 
LA solutions.
The only study that included a detailed 
physical examination of the patient was that of 
Hillerup and Jensen,18 using a ‘standardised test 
of neurosensory functions’ by a single operator 
to determine the presence and extent of any 
reported nerve damage.31,32 The remaining 
included studies merely noted the incidence 
of ‘reported’ nerve damage.
Pogrel’s studies,20,26 using data from a special-
ist centre and Garisto and Gaffen’s paper,27 all 
failed to accurately examine the patient, relying 
instead on the patient’s own descriptions and 
a log of reported cases to the adverse event 
reporting system (AERS). Pogrel’s description 
of the patient ‘examination’ lacks sufficient 
detail to allow exclusion of detection bias.
The description of the reporting of an 
‘electric shock’ during the administration of 
the LA created notable discussion among the 
included authors. Four of the included papers 
noted the reporting of this phenomenon17,18,27,28 
and all included these reports in their results 
as a ‘nerve injury’. The remaining three papers 
failed to mention this possible event.19,20,26
Interestingly, Hillerup and Jensen state 
that ‘electric shock per se is probably of 
minor relevance for the aetiology of injection 
injuries.’18 However, they then go on to 
question the cause of nerve injury, admitting 
that it is unknown as to whether the nerve is 
damaged via neurotoxicity or mechanically, via 
intra-fascicular injection.
Many authors are now advocating the use 
of 4% articaine in infiltration anaesthesia as 
an alternative to block anaesthesia due to 
the increased efficacy of this agent.33–36 The 
evidence presented in these studies indicates 
a clear efficacy advantage when using 4% 
articaine as a buccal infiltration compared 
to 2% lidocaine in an IANB. One author has 
even suggested that the IANB may now be an 
unnecessary procedure.37
Concentration of the LA agent
Three of the chosen papers postulate that it may 
be the fact that, because articaine is adminis-
tered in a 4% solution, it is the concentration 
of the LA solution rather than the actual phar-
macology of the agent that causes damage to 
the nerve.17,27,28 This suggestion would appear 
to be confirmed by another study on rat sciatic 
nerves, which concluded that significantly more 
neurotoxic injuries were observed following the 
direct injection into the nerve of a 4% articaine 
solution compared to that of a 2% solution.38
In a recent in vitro study, articaine proved to 
be less neurotoxic than lidocaine, mepivacaine 
and prilocaine.39 Indeed, previous studies have 
concluded that no scientific evidence exists to 
confirm the suggestion that articaine causes 
increased paraesthesia and, to date, no causal 
relationship has been exhibited between an 
anaesthetic agent’s concentration and neuro-
logical damage.40,41
Implications for clinical research
This mini systematic review confirms that 
controversy still exists over the safety of 4% 
articaine and 1:100,000 adrenaline as a dental 
local anaesthetic agent.
The authors of all the included papers admit 
that, due to the extremely rare occurrence of 
the outcome, a carefully performed, high 
quality DBRCT would have to involve such 
vast numbers of participants that, logistically, 
such a study would pose certain problems.
It is generally accepted that 4% articaine 
exhibits greater lipid solubility, faster onset 
and increased duration of anaesthesia, more 
profound anaesthesia, and reduced toxicity 
than those of its counterpart, 2% lidocaine. 
With these favourable attributes, 4% articaine 
does indeed offer superior properties over 2% 
lidocaine but would a 2% articaine solution 
offer the same advantages?
Further research is required into the efficacy 
and safety of a 2% articaine solution. Indeed, 
a study in 2006 proved that the 4% articaine 
solution was not superior in its anaesthetic 
effect compared to 2% and 3% solutions of the 
same agent.42
Implications for general dental practice
The highest level of evidence available to this 
study was that of Malamed and Gagnon’s 
DBRCT in 2001.19 Although spread over 27 
sites in two countries, this trial unfortunately 
exhibited several potential areas of bias. It did, 
however, conclude that there was no evidence 
to suggest that 4% articaine posed a greater risk 
of nerve damage than 2% lidocaine and that the 
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use of 4% articaine in general dental practice 
can, therefore, be deemed safe and efficient.
Three further papers, not included in this 
study, also concluded that no conclusive 
evidence exists to suggest that 4% articaine 
poses a greater risk of nerve damage compared 
to other LA agents.3,10,12
Conclusion
This mini systematic review of the literature 
has highlighted the fact that further research 
is required to determine the relative risks of 
using 4% articaine compared to 2% lidocaine 
in IANBs. Clearly, the use of 4% articaine is 
becoming increasingly popular as a means of 
achieving successful dental anaesthesia and, 
if current trends continue, this agent may 
become the number one anaesthetic of choice 
in the future. This steady increase in popular-
ity is likely to be due to the proven efficacy of 
this LA agent, benefiting both the patient and 
the operator. Indeed, the incidence of inferior 
alveolar nerve damage may reduce in the future 
as more evidence emerges to support infiltration 
anaesthesia. With this in mind, and consider-
ing the contradictory evidence presented in this 
study, it is suggested that until factual evidence 
becomes available, dental practitioners should 
consider all the potential risks and benefits of a 
particular LA agent prior to its administration.
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Table 1  The hierarchy of evidence. Adapted from the Scottish Intercollegiate Guidelines Network (SIGN)43
Level of evidence Description of evidence
1++ High quality meta-analysis, systematic reviews of RCTs or very low risk of bias RCTs
1+ Well conducted meta-analysis, systematic reviews of RCTs or very low risk of bias RCTs
1- Meta-analysis, systematic reviews of RCTs or RCTs with a high risk of bias
2++ High quality systematic reviews of cohort or case-control studies or high quality cohort or case-control studies with a very low risk of confounding 
bias or chance and a high probability that the relationship is causal
2+ Well conducted cohort or case-control studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal
2- Cohort or case-control studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal
3 Non-analytical studies. Case reports and case series
4 Expert opinion
Table 2  PICOS parameters applied to the study
PICOS Search strategy application
Population Patients receiving IANBs with either 4% articaine hydrochloride + 1:100,000 adrenaline or patients receiving IANBs with 2% lidocaine + 1:100,000  
adrenaline. Males and females. All ages
Intervention Studies involving the administration of an IANB with 4% articaine + 1:100,000 adrenaline
Comparison Studies involving the administration of an IANB with 2% lidocaine +1:100,000 adrenaline
Outcome Post injection nerve damage indicated by prolonged temporary or permanent anaesthesia, paraesthesia or dysaesthesia in both the intervention and comparison groups
Studies Randomised controlled trials comparing 4% articaine + 1:100,000 adrenaline + 2% lidocaine + 1:100,000 adrenaline in IANBs. Cohort studies investigating 
the use of 4% articaine + 1:100,000 adrenaline as a dental local anaesthetic agent in IANBs.
Table 3  Search inclusion criteria
Inclusion criteria Reason for inclusion
English language papers No translation facility. Author only speaks English.
Papers published since 1976 Articaine’s first use in clinical dentistry
Human subjects only Relevant to general dental practice
Male and female subjects Maximum number of participants
Global participation Maximum number of participants
Subjects of all ages Maximum number of participants
Articles involving IANB anaesthesia Specific to study question
LA agents, lidocaine and articaine only Specific to study question
Inferior alveolar and/or lingual nerve damage Anatomical possibility of damage to either nerve during the administration of an IANB.
Permanent and/or temporary nerve damage Both indicators of nerve damage
Suitable ethical approval obtained Ethical and moral issues relating to research
Random controlled trials Good quality evidence
Cohort studies Large number of subjects
Table 4  Search exclusion criteria
Exclusion criteria Reason for exclusion
Articles describing only infiltration anaesthesia Administration of a nerve block is postulated as a cause of nerve damage
Articles describing the use of anaesthetic agents other than articaine or lignocaine Other anaesthetic agents not widely used in general dental practice
Studies investigating the use of articaine for ‘surgical dentistry’ Possible surgical cause of nerve damage
Studies investigating the use of articaine for removal of lower third molars and  
placement of mandibular implants
Both recognised causes of possible inferior alveolar and lingual nerve paraesthesia
‘Sponsored’ articles, unless a conflict of interest is declared Author bias
Case studies Poor quality evidence
Letters to editors Personal opinions
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Table 5  Search strategy, 18 November 2016
Search no. Search term
S1 (MM ‘carticaine’)
S2 septanest
S3 articaine
S4 ultracaine
S5 septocaine
S6 (MM ‘anesthesia, dental+’)
S7 lignocaine
S8 lidocaine
S9 xylocaine
S10 S1 or S2 or S3 or S4 or S5 or S6
S11 S7 or S8 or S9
S12 paraesthesia
S13 paresthesia
S14 anaesthesia
S15 anesthesia
S16 dysaesthesia
S17 dysesthesia
S18 (MM ‘trigeminal nerve injuries+’)
S19 damage
S20 injury
S21 inferior alveolar nerve
S22 inferior dental nerve
S23 mandibular nerve
S24 lingual nerve
S25 S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20
S26 S21 or S22 or S23 or S24
S27 S10 and S11 and S25 and S26
Table 6  Methodology index for non randomised studies (MINORS)25
Methodological items for  
non-randomised studies
Item description
Clearly stated aim Relevant and precise study question, relating to available literature
Inclusion of consecutive patients All eligible participants included in study
Prospective collection of data Data collected as per guidelines established prior to study commencement
Endpoints appropriate to study aim Clear, quantifiable outcome addressing study question
Unbiased endpoint Blind assessment of endpoint
Review period appropriate to aim Review period sufficient to allow outcome occurrence and measurement
Attrition bias less than 5% All patients should be reviewed
Prospective calculation of study size Information regarding study population size necessary to achieve 95% confidence interval and level of statistical significance
Additional items for use in comparative studies Item description
Suitable control ‘Gold-standard’ as per available information
Contemporary groups Groups studies during the same time period
Baseline equivalent groups Group criteria similar at start point
Statistical analysis Suitable statistics with confidence intervals or relative risk
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Table 7  MINORS criteria scores
Item score Reason
0 Not reported
1 Reported but inadequate
2 Reported and adequate
Table 8  Search strategy and results (performed on 30 December 2016)
Search no. Search term Dentistry & oral science Medline Cochrane
S1 (MM ‘carticaine’) 2 303 3
S2 septanest 2 4 1
S3 articaine 216 398 3
S4 ultracaine 4 47 9
S5 septocaine 6 3 1
S6 (MM ‘Anesthesia, Dental+’) 1,277 5,827 9
S7 lignocaine 332 2,405 11
S8 lidocaine 561 25,426 47
S9 xylocaine 306 713 1
S10 S1 or S2 or S3 or S4 or S5 or S6 1,429 6,139 9
S11 S7 or S8 or S9 592 26,463 55
S12 paraesthesia 117 1,134 195
S13 paresthesia 31 7,415 50
S14 anaesthesia 6,591 65,803 1078
S15 anesthesia 6,591 200,202 334
S16 dysaesthesia 24 265 23
S17 dysesthesia 61 1278 13
S18 (MM ‘trigeminal nerve injuries+’) 84 833 13
S19 damage 3,284 433,750 2,568
S20 injury 9,260 549,161 2,570
S21 inferior alveolar nerve 1124 2,102 13
S22 inferior dental nerve 78 142 18
S23 mandibular nerve 568 3,556 36
S24 lingual nerve 269 1,298 18
S25 S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 18,767 1,145,705 4,497
S26 S21 or S22 or S23 or S24 1,492 5281 55
S27 S10 and S11 and S25 and S26 36 170 2
Table 9  Included studies
Title and author(s) Year ‘SIGN’ Level 
of evidence
Type of study
A 21-year retrospective study of reports of paresthesia following local anesthetic administration. Hass and Lennon17 1995 2- Retrospective cohort
Retrospective review of voluntary reports of nonsurgical paresthesia in dentistry. Gaffen and Haas28 2009 2- Retrospective cohort
Nerve injury caused by mandibular block analgesia. Hillerup and Jenson18 2006 2- Retrospective cohort
Permanent nerve damage from inferior alveolar nerve blocks – an update to include articaine. Pogrel26 2007 2- Retrospective cohort
Articaine hydrochloride: a study of the safety of a new amide local anesthetic. Malamed, Gagnon et al.19 2001 1- Random controlled trials
Occurrence of paresthesia after dental local anesthetic administration in the United States. Garisto, Gaffen et al.27 2010 2- Retrospective cohort
Permanent nerve damage from inferior alveolar nerve blocks: a current update. Pogrel20 2012 2- Retrospective cohort
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Table 10  Examples of excluded studies
Article(s) Reason for exclusion
Aguiar, Chebroux et al.44
Hung, Chang et al.45
Potocnik, Tomsic et al.46
Sisk47
Baroni, Franz-Montan et al.48
Batista, Berto et al.49
Incorrect population. n = 6
Studies on rats and cats
Studies using Cow–Gates and Akinosi IANB
Studies of mental and incisive nerve blocks
Chopra, Jindal et al.50
Danielsson, Evers et al.51
Rood52
Incorrect intervention. n = 48
Studies comparing lidocaine, etidocaine and bupivacaine
Rood52 Incorrect comparator. n = 1
5% lidocaine solution used in study
Ahmad, Ravikumar et al.53
Kambalimath, Dolas et al.54
Moorthy, Stassen55
Choi, Seo et al.56
Al-Sandook, Al-Saraj57
Incorrect outcome. n = 42
Studies measuring articaine’s efficacy only
Studies detailing damage to nerves other than IAN and/or LN
Choi, Seo et al.56
Wyman58
Pedlar59
Incorrect studies. n = 8
Case reports and letters to editors
Fowler, Reader60
Steinkruger, Nusstein et al.61
Articles not answering study question. n = 66
Studies comparing volume of anaesthetic agent and injection technique
Table 11  MINORS checklist for included studies
Criteria Haas & 
Lennon17
Gaffen & 
Haas28
Hillerup & 
Jenson18
Pogrel26 Malamed & 
Gagnon19
Garisto & 
Gaffen27
Pogrel20
Clearly stated aim 2 2 2 2 2 2 2
Inclusion of consecutive patients 1 2 2 2 1 2 2
Prospective collection of data 2 2 2 2 2 2 2
Endpoint appropriate to study 2 2 2 2 2 2 2
Unbiased assessment of endpoint 1 1 1 1 2 1 1
Appropriate follow-up period 0 1 2 2 1 1 2
Loss to follow-up less than 5% 1 0 0 0 0 0 0
Prospective calculation of study size 0 0 0 0 0 0 0
Adequate control group N/A N/A N/A N/A 2 N/A N/A
Contemporary groups N/A N/A N/A N/A 2 N/A N/A
Baseline equivalence groups N/A N/A N/A N/A 2 N/A N/A
Adequate statistical analysis N/A N/A N/A N/A 1 N/A N/A
Total score 9 10 11 11 17 10 11
Table 12  Risk of assessment bias24
Bias Malamed and Gagnon19
Random sequence generation (selection bias) Low risk ‘There were no statistically significant differences in the studies between the articaine and lidocaine treatment groups 
with respect to age, sex, weight, race distribution or the proportion of subjects undergoing simple or complex procedures’
Allocation concealment (selection bias) Unclear risk. Not mentioned in methodology
Blinding of outcome assessment (detection bias) Unclear risk. ‘Randomised, double-blind…’ mentioned in methodology but no other details
Participant awareness (performance bias) Unclear risk. Not mentioned in methodology
Incomplete outcome data (attrition bias) High risk. No mention of attrition at 24 hour and 7 day follow-up interviews
Sponsorship (funding bias) Low risk. ‘The manufacturer of the drug products used in the three trials...providing materials and funding.’ The same 
company manufactures both the intervention and comparator drugs
Selective reporting (reporting bias) Unclear risk. ‘The vast majority of these events are related by (telephone interviews with) patients and are alleged not confirmed’
Overall risk of bias Unclear risk.
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Table 13b Data extraction
Study Pogrel26 Malamed, Gagnon et al.19 Garisto, Gaffen et al.27 Pogrel20
Study publication date April 2007 February 2001 July 2010 October 2012
Study design Retrospective cohort 3 double blind random  
controlled trials
Retrospective cohort Retrospective cohort
Study objectives Prolonged IAN/LN paraesthesia 
following LA in dentistry
Direct comparison of efficacy and 
safety between 4% articaine and 
2% lidocaine
Record incidence of nerve dam-
age after LA in dentistry
Prolonged IAN/LN paraesthesia 
following LA in dentistry
Geographical origin Maxillofacial Dept, UCSF, USA 27 sites, 8 in the UK and 19 in 
the USA
USA Maxillofacial Dept, UCSF, USA
Study setting Primary and secondary dental care No stated Voluntary reports to FDA’s AERS Primary and secondary dental care
Study funding Not stated ‘Materials and funding’ provided by 
manufacturers of the LA agents
No ‘disclosures’ reported by 
authors
Not stated
Eligible study participants 57, sex and ages not stated 1325, male and female, aged 
4–80 years
226, male and female, 15–78 
years
38, sex and ages not stated
LA agents used Lidocaine, articaine, prilocaine, 
mepivacaine, bupivacaine
2% Lidocaine, 4% articaine, Lidocaine, articaine, prilocaine, 
mepivacaine, bupivacaine
Lidocaine, articaine, prilocaine, 
carbocaine
Outcome reporting and 
recording
Examination of patient at UCSF. 
Details of examination not 
stated
Interviews and telephone calls to 
the patients. No further details of 
examination
Voluntary reports to FDA’s 
AERS.
Duration of paraesthesia noted
Examination of patient at UCSF. 
Details of examination not 
stated
Comparison made between 
‘expected’ and ‘observed’ 
outcomes
Yes No Yes Yes
Study period 3 years. 01/01/03–31/12/05 Not stated 11 years, November 1997–
August 2008
6 years, 01/01/06–31/12/11
Attrition bias Not stated 3 patients lost to follow up (0.23%) Not stated Not stated
Data analysis of outcomes Narrative Narrative Descriptive statistical analysis Narrative
Ethical approval Not stated Stated as obtained in UK and USA Stated as obtained and approved 
by University of Toronto
Not stated
Table 13a Data extraction
Study Haas & Lennon17 Gaffen & Haas28 Hillerup & Jensen18
Study publication date April 1995 October 2009 May 2006
Study design Retrospective cohort Retrospective cohort Retrospective cohort
Study objectives Prolonged paraesthesia following LA 
in dentistry
Prolonged paraesthesia following LA 
in dentistry
Prolonged paraesthesia following LA in 
dentistry
Geographical origin Ontario, Canada Ontario, Canada Denmark
Study setting Not stated Not stated ‘All dental practitioners’
Study funding Not stated ‘no declared financial interests’ Not stated
Eligible study participants 143, male and female, all ages 172, male and female, 11–80 years 52, male and female, 24–81 years
LA agents used Lidocaine, articaine, prilocaine,  
mepivacaine, bupivacaine
Lidocaine, articaine, prilocaine,  
mepivacaine, bupivacaine
Lidocaine, articaine, prilocaine,  
mepivacaine
Outcome reporting and recording Voluntary reports to PLP Voluntary reports to PLP Telephone call to GDP. Type and volume of LA 
used. Electric shock experienced?
Written questionnaires and patient interviews
Comparison made between 
‘expected’ and ‘observed’ outcomes
Yes Yes No
Study period 21 years, 1973–1993 10 years, 1999–2008 8 years, 1997–2004
Attrition bias Not stated Not stated 30 patients (58%) lost to follow up after 12 months
Data analysis of outcomes Chi: square analysis Chi: square analysis Chi: square analysis
Ethical approval Not stated Stated obtained Not stated
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Table 14  Summary of outcome characteristics of included studies
Study Design Number of eligible 
participants with 
outcome<b>*</b>
Number of participants 
with outcome following 
intervention (articaine)
Number of participants 
with outcome following 
comparison (lidocaine)
Reported outcomes
Haas & Lennon17 Retrospective cohort 143<b>*</b> 50 5 Paraesthesia following the injection 
of LA in non-surgical dentsistry
Gaffen & Haas28 Retrospective cohort 172* 109 23 Non-surgical paraesthesia
Hillerup & Jensen18 Retrospective cohort 52<b>*</b> 29 10 Non-surgical IAN or LN injury 
following a unilateral IANB
Pogrel26 Retrospective cohort 57<b>*</b> 17 20 Damage to IAN or LN following 
an IANB
Malamed, Gagnon 
et al.19
Double-blind random 
controlled trial
13 8 5 ‘Numbness or tingling 4 – 8 days 
after the procedure’
Garisto, Gaffen et al.27 Retrospective cohort 226<b>*</b> 116 11 Oral paraesthesia following 
dental treatment
Pogrel20 Retrospective cohort 38<b>*</b> 14 10 Damage to IAN or LN following 
an IANB
*In all the included studies except Malamed, Gagnon et al., agents other than articaine and lidocaine were also studied and included in the study results. The inclusion of prilocaine, mepivacaine, bupivacaine  
and carbocaine explains the discrepancy between the sum of the intervention (articaine) and comparison (lidocaine) participants and that of the number of eligible participants in each study.
Table 15a Summary of study findings
Study Haas & Lennon17 Gaffen & Haas28 Hillerup & Jensen18
Number of incidences of IAN damage with articaine Not reported Not reported 5
Number of incidences of LN damage with articaine Not reported Not reported 24
Number of incidences of IAN and/or LN damage with articaine 50 (33.6%) 109 (59.9%) 29 (54%)
Number of incidences of IAN damage with lidocaine Not reported Not reported 3
Number of incidences of LN damage with lidocaine Not reported Not reported 7
Number of incidences of IAN and/or LN damage with lidocaine 5 (3.4%) 23 (12.6%) 10 (19%)
Expected frequency of IAN and/or LN damage with articaine<b>*</b> 5.3 26.5 Not reported
Observed frequency of IAN and/or LN damage with articaine 10 42 Not reported
Expected frequency of IAN and/or LN damage with lidocaine<b>*</b> 3.7 23.8 Not reported
Observed frequency of IAN and/or LN damage with lidocaine 0 6 Not reported
*Expected frequencies calculated using the ‘null hypothesis’.29
Table 15b Summary of study findings
Study Pogrel26 Malamed, Gagnon et al.19 Garisto, Gaffen et al.27 Pogrel20
Number of incidences of IAN damage with articaine Not reported Not reported Not reported Not reported
Number of incidences of LN damage with articaine Not reported Not reported Not reported Not reported
Number of incidences of IAN and/or LN damage with articaine 17 (29.8%) 8 (1%) 116 (51.3%) 14 (37%)
Number of incidences of IAN damage with lidocaine Not reported Not reported Not reported Not reported
Number of incidences of LN damage with lidocaine Not reported Not reported Not reported Not reported
Number of incidences of IAN and/or LN damage with lidocaine 20 (35%) 5 (1%) 11 (4.9%) 10 (26%)
Expected frequency of IAN and/or LN damage with articaine Not reported Not reported 32 Not reported
Observed frequency of IAN and/or LN damage with articaine Not reported Not reported 116 Not reported
Expected frequency of IAN and/or LN damage with lidocaine Not reported Not reported 130 Not reported
Observed frequency of IAN and/or LN damage with lidocaine Not reported Not reported 10 Not reported
*Expected frequencies calculated using the ‘null hypothesis’.29
RESEARCH
10 BRITISH DENTAL JOURNAL  |  VOLUME 226  NO. 3  |  FEBRUARY 8 2019
MSS_18_270.indd   10 24/01/2019   17:45
Appendix 1  Glossary of abbreviations
AERS: Adverse Event Reporting System
DBRCT: Double Blind Random Controlled Trial
IAN: Inferior Alveolar Nerve
IANB: Inferior Alveolar Nerve Block
LA: Local Anaesthetic
LN: Lingual Nerve
MeSH: Medical Sub Headings
MINORS: Methodological Index for Non-Randomised Studies
PICOS: Population, Intervention, Comparator, Outcome, Studies
PRISMA: Preferred Reporting Items for Systematic reviews and Meta-Analyses
SIGN: Scottish Intercollegiate Guidelines Network
UCSF: University of California, San Francisco
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